Менопаузальная гормонотерапия: максимальная польза при минимальных рисках
Аннотация
Статья посвящена рассмотрению современных положений о возможных рисках современной менопаузальной гормонотерапии, ее пользе при своевременном ее дебюте, индивидуальном выборе и длительном применении с минимизацией дозы.
Об авторах
В. Е. Балан
ГБУЗ МО «Московский областной научно-исследовательский институт акушерства и гинекологии»
Россия
Россия
Е. В. Тихомирова
ГБУЗ МО «Московский областной научно-исследовательский институт акушерства и гинекологии»
Россия
Россия
Список литературы
1. Сметник В. П. Приливы: загадка климактерия // Климактерий. Медицинский научно-реферативный журнал Российской ассоциации по менопаузе. 2009. № 1. С. 3-4.
2. Freeman E. W., Sherif K. Prevalence of hot flushes and night sweats around the world: a systematic review // Climacteric. 2007. № 10 (3). Р. 197-214.
3. Raus K. Выступление на конференции Pres 2011 - Gynecology and Urology. Phytoneering research and experience summit (Майорка, 2011). Botanical Medicine for Womens Health, 2011.
4. Geller S. E. et all. Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: a randomized controlled trial // Menopause. 2009. Nov-Dec. № 16 (6). Р. 1156-1166.
5. Birge S. J. Estrogen and the brain: implications for menopause management // In: Menopause. The State of the Art-reserch and management / Ed. P. G. Schneider. The Parthenon Publishing Group, 2002. P. 191-195.
6. Pines A. Vasomotor symptoms and cardiovascular disease risk // Climacteric 2011. Vol. 14. P. 535-536.
7. Nelson H. D. Menopause. Lancet 2008; 371: 760-770.
8. Whiteley J., Wagner J. S., Bushmakin A., Kopenhafer L., Dibonaventura M., Racketa J. Impact of the severity of vasomotor symptoms on health status, resource use, and productivity. Menopause 2013; 20: 518-524.
9. Avis N. E., Crawford S. L., Greendale G. et al; Study of Women’s Health Across the Nation. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med 2015; 175: 531-539.
10. Thurston R. C., Sutton-Tyrrell K., Everson-Rose S. A., Hess R., Matthews K. A. Hot flashes and subclinical cardiovascular disease: findings from the Study of Women’s Health Across the Nation Heart Study. Circulation 2008; 118: 1234-1240.
11. Maki P. M. Verbal memory and menopause. Maturitas 2015; 82: 288-290.
12. Maclennan A. H., Broadbent J. L., Lester S., Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004; 4: CD 002978.
13. The 2017 Hormone Therapy Position Statement of the North American Menopause Society. Menopause 2017; 24 (7): 728-753.
14. Юренева С. В., Ильина Л. М. «Старение репродуктивной системы женщин: от теории к практике. Часть II: Роль гормональной терапии в решении проблем переходного периода и ранней менопаузы». Акушерство и гинекология, 2014, 4, 17-24.
15. Attarian H., Hachul H., Guttuso T., Phillips B. Treatment of chronic insomnia disorder in menopause: evaluation of literature. Menopause 2015; 22: 674-684.
16. Joffe H., Massler A., Sharkey K. M. Evaluation and management of sleep disturbance during the menopause transition. Semin Reprod Med 2010; 28: 404-421.
17. Schu"ssler P., Kluge M., Yassouridis A. et al. Progesterone reduces wakefulness in sleep EEG and has no effect on cognition in healthy postmenopausal women. Psychoneuroendocrinology 2008; 33: 1124-1131.
18. Moorman P. G., Myers E. R., Schildkraut J. M., Iversen E. S., Wang F., Warren N. Effect of hysterectomy with ovarian preservation on ovarian function. Obstet Gynecol 2011; 118: 1271-1279.
19. Trabuco E. C., Moorman P. G., Algeciras-Schimnich A., Weaver A. L., Cliby W. A. Association of ovary-sparing hysterectomy with ovarian reserve. Obstet Gynecol 2016; 127: 819-827.
20. Atsma F., Bartelink M. L., Grobbee D. E., van der Schouw Y. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 2006; 13: 265-279.
21. Mondul A. M., Rodriguez C., Jacobs E. J., Calle E. E. Age at natural menopause and cause-specific mortality. Am J Epidemiol 2005; 162: 1089-1097.
22. Muka T., Oliver-Williams C., Kunutsor S. et al. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis. JAMA Cardiol 2016; 1: 767-776.
23. Mondul A. M., Rodriguez C., Jacobs E. J., Calle E. E. Age at natural menopause and cause-specific mortality. Am J Epidemiol 2005; 162: 1089-1097.
24. Muka T., Oliver-Williams C., Kunutsor S. et al. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis. JAMA Cardiol 2016; 1: 767-776.
25. Hong J. S., Yi S. W., Kang H. C. et al. Age at menopause and cause-specific mortality in South Korean women: Kangwha Cohort Study. Maturitas 2007; 56: 411-419.
26. Mikkola T. S. et al. New evidence for cardiac benefit of postmenopausal hormone therapy. Climacteric, 2017; 20: 1, 5-10.
27. Mueck А. О., Harald Seeger et al. «Use of dydrogesterone in hormone replacement therapy». Maturitas 2009, 51-60.
28. Менопауза и климактерическое состояние у женщины. Клинические рекомендации РОАГ. КР 117. 2016. - 45 с.
29. R. J. Baber et al. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy, Climacteric, 19: 2, 109-150.
30. The 2017 hormone therapy position statement of The North American Menopause Society / Menopause: The Journal of The North American Menopause Society. Vol. 24, No. 7, pp. 728-753
31. Leeangkoonsathian E., Pantasri T., Chaovisitseree S., Morakot N. The effect of different progestogens on sleep in postmenopausal women: a randomized trial. Gynecol Endocrinol. 2017 Dec; 33 (12): 933-936.
32. Schneider C et al. Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations. Climacteric 2009; 12: 514-24.
33. Fournier A. et al. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E 3N cohort study. Breast Cancer Res Treat 2008; 107: 103-11.
34. Lyytinen H. et al. Breast cancer risk in postmenopausal women using estradiol-pro-gestogen therapy. Obst Gyn 2009; 113: 65-73.
35. Jo Ann, E. Manson, Aaron K. Aragaki, Jacques E. Rossouw, et al. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality The Women’s Health Initiative Randomized Trials. JAMA. 2017; 318 (10): 927-938.
36. Piróg M. et al. Differential effect of the ultra-low dose and standard estrogen plus dydrogesterone therapy on thrombin generation and fibrinolysis in postmenopausal women. Acta Obstet Gynecol Scand. 2017 Oct 5. doi: 10.1111/aogs.13239. [Epub ahead of print]
Рецензия
Для цитирования:
Балан В.Е., Тихомирова Е.В. Менопаузальная гормонотерапия: максимальная польза при минимальных рисках. Медицинский алфавит. 2018;1(6):6-9.
For citation:
Balan V.E., Tikhomirova E.V. Menopausal hormone therapy: maximum benefit with minimal risks. Medical alphabet. 2018;1(6):6-9. (In Russ.)
Просмотров:
273
Послать статью по эл. почте 